Hofseth Biocare ASA, commonly referred to as Hofseth Biocare, is a leading player in the biotechnology and health supplement industry, headquartered in Norway. Founded in 2009, the company has established itself as a pioneer in the development of high-quality marine ingredients, focusing on sustainable practices and innovative extraction methods. With operations primarily in Norway and a growing presence in international markets, Hofseth Biocare offers a range of unique products, including omega-3 fatty acids, collagen peptides, and other bioactive compounds derived from fish. Their commitment to sustainability and quality has positioned them as a trusted supplier in the health and wellness sector, earning recognition for their advanced research and development initiatives. As a result, Hofseth Biocare continues to make significant strides in promoting health through marine biotechnology.
How does Hofseth Biocare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hofseth Biocare's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Hofseth Biocare reported total carbon emissions of approximately 14,930,000 kg CO2e. This figure includes Scope 1 emissions of about 1,616,000 kg CO2e, Scope 2 emissions of approximately 48,000 kg CO2e, and Scope 3 emissions, which comprise upstream transportation and distribution at about 445,000 kg CO2e and downstream transportation and distribution at approximately 1,453,000 kg CO2e. Comparatively, in 2023, the company recorded total emissions of about 21,548,749 kg CO2e, with Scope 1 emissions at approximately 1,850,000 kg CO2e and Scope 2 emissions at around 46,000 kg CO2e. This indicates a significant reduction in total emissions from 2023 to 2024. Hofseth Biocare has not set specific reduction targets under the Science Based Targets initiative (SBTi) nor does it have documented climate pledges. The company’s emissions data is self-reported and does not cascade from a parent organization, indicating that it operates independently in its climate reporting. Overall, Hofseth Biocare is actively monitoring its carbon footprint, with a focus on reducing emissions across all scopes, although specific reduction initiatives or targets have not been disclosed.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,619,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 90,400 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | 0,000,000 |
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 53% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hofseth Biocare has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
